Evidence map›Paper›PMID 34142069›Full record

ArticleEClinicalMedicine2021

Hepatocellular carcinoma amongst Aboriginal and Torres Strait Islander peoples of Australia.

Alan J Wigg, Sumudu K Narayana, Gunter Hartel, Linda Medlin, Greg Pratt, Elizabeth E Powell, Paul Clark, Jane Davies, Kirsty Campbell, Maree Toombs and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EClinicalMedicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 2 pooled it
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 31 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Observational
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 9 institutions in 1 country.

Alan J WiggHepatology and Liver Transplant Medicine Unit, Southern Adelaide Local Health Network, Adelaide, SA, Australia.
Sumudu K NarayanaHepatology and Liver Transplant Medicine Unit, Southern Adelaide Local Health Network, Adelaide, SA, Australia.
Gunter HartelQIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
Linda MedlinAboriginal and Torres Strait Islander Health and Wellbeing, Central Queensland Hospital and Health Service, Queensland, Australia.
Greg PrattQIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
Elizabeth E PowellDepartment of Gastroenterology and Hepatology, Princess Alexandra Hospital, Brisbane, Queensland, Australia.
Paul ClarkMater Hospitals, Brisbane, Queensland, Australia.
Jane DaviesMenzies School of Health Research, Royal Darwin Hospital, Darwin, The Northern Territory, Australia.
Kirsty CampbellRoyal Darwin Hospital, Darwin, The Northern Territory, Australia.
Maree ToombsUniversity of Queensland, Herston, Queensland, Australia.
Michael LarkinThe Aboriginal Health Council of South Australia, Adelaide, Australia.
Patricia C ValeryQIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
QIMR Berghofer Medical Research Institute · AUFlinders University · AUAboriginal Health Council of South Australia · AUChildren’s Health Queensland Hospital and Health Service · AUMater Adult Hospital · AUMenzies School of Health Research · AURoyal Darwin Hospital · AUThe University of Queensland · AUTranslational Research Institute · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLiver disease and hepatocellular carcinoma (HCC) are important contributors to the mortality gap between Indigenous and non-Indigenous Australians. However, there is a lack of population based high quality data assessing the differences in HCC epidemiology and outcomes according to Indigenous status. The aim of this study was therefore to perform a large epidemiological study of HCC investigating differences between Indigenous and non-Indigenous Australians with HCC.

methodsStudy design was a retrospective cohort study. Data linkage methodology was used to link data from cancer registries with hospital separation summaries across three Australian jurisdictions during 2000-2017. Cumulative survival (Kaplan-Meier) and the differences in survival (Multivariable Cox-regression) by Indigenous status were assessed.

findingsA total of 229 Indigenous and 3587 non-Indigenous HCC cases were included in the analyses. Significant epidemiological differences identified for Indigenous HCC cases included younger age at onset, higher proportion of females, higher rurality, lower socioeconomic status, and higher comorbidity burden (all

interpretationSuch data provide a call to action to help design and implement health literacy, liver management and HCC surveillance programs for Indigenous people to help close the liver cancer mortality gap.

Indexed as

EpidemiologyIndigenous AustraliansLiver cancerSurvival

Identifiers

PMID34142069
PMCPMC8187829
OpenAlexW3169480264

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.